Venous Thromboembolism Treatment Market Expected to Reach US$ 5,972.3 Mn by 2025
Analyst Speak:
“The Global Venous Thromboembolism Treatment Market is expected to grow at a significant CAGR over seven years forecast period 2019-2025 to reach US$ 5,972.3 Mn by 2025 owing to rising prevalence of venous thromboembolism across the globe”
Precision Business Insights (PBI) in its report titled “Global Venous Thromboembolism Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
The global venous thromboembolism treatment market growing at a CAGR of XX% over the forecast period to reach US$ 5,972.3 Mn by 2025 owing to increasing prevalence of venous thromboembolism around the globe. Moreover, rise in R&D for the development of newer drugs, strong product pipeline, rise in number of surgical procedures, grow in geriatric population, and increase in healthcare expenditure are anticipated to propel the global venous thromboembolism treatment market over the forecast years. However, stringent regulations for the product approval, lack of disease awareness in underdeveloped countries, high cost of treatment, and side effects with venous thromboembolism treatment are hamper the growth of venous thromboembolism treatment market over the forecast timeframe.
Global venous thromboembolism treatment market segmented on the basis of drug class, disease type, distribution channel, and region.
Request Sample Report:
https://www.precisionbusinessinsights.com/request-sample?product_id=16300
Antiviral Drugs segment accounted for higher revenue share
Based on drug class, global venous thromboembolism treatment market segmented into oral anticoagulants, thrombolytic therapy, plasminogen activators, and others. Oral anticoagulants market accounted US$ XX Mn in 2018 and projected to dominate over the forecast period due to frequent product approval and launch of new products in the market. For instance, in December 2018, Janssen Pharmaceuticals, Inc. submitted Supplemental New Drug Application (sNDA) to FDA for XARELTO (rivaroxaban) for the treatment of venous thromboembolism. Moreover, launch of generics and high awareness about the oral anticoagulants among the physicians are anticipated to boost the market.
North America is expected to dominate Global Venous Thromboembolism Treatment Market
PBI’s global venous thromboembolism treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America is anticipated to dominated the market in 2018 and the same trend is projected to follow over 2019-2025 owing to surge in prevalence of venous thromboembolism in USA. As per Centre for Disease Control and Prevention (CDC), approximately 900,000 people affected with VTE each year. Moreover, increase in healthcare expenditure, favorable reimbursement policies, and presence of huge number of market players are surge the market over the forecast timeframe. Europe venous thromboembolism market is anticipated to grow rapidly owing to the large patient pool, rise in number of surgical procedures, and increase in R&D activities are anticipated to boost the market over the forecast years.
Key Developments
- In June 2017, Partola Pharmaceuticals received FDA approval for BEVYXXA (Betrixaban) used in the treatment of venous thromboembolism in adults
Key player’s profiles in the report are Partola Pharmaceuticals. Janssen Pharmaceuticals, Inc., Daiichi Sankyo Co. Ltd., Pfizer, Inc., AbbVie, Inc., Wockhardt Ltd., Merck & Co., Inc., Astellas Pharma, Inc., Bayer AG, Abbott Laboratories, and Bristol Myers Squibb, Inc.
Detailed Segmentation
By Drug Class
- Oral Anticoagulants
- Thrombolytic Therapy
- Plasminogen Activators
- Others
- Deep vein thrombosis
- Pulmonary embolism
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Disease Type
By Distribution Channel
Geography
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
- Rest of MEA
For More Information:
About Us:
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
Contact Us: Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com